Vitrakvi (larotrectinib)

pCPA File Number: 21598
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.
Sponsor/Manufacturer:
Bayer Inc.
CADTH Project Number:
PC0221-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable